GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior

Neuropsychopharmacology

Volumn 38, Issue 7, 2013, Pages 1221-1233

  Hanson, Jesse E ^a   Weber, Martin ^a   Meilandt, William J ^a   Wu, Tiffany ^a   Luu, Tom ^a   Deng, Lunbin ^a   Shamloo, Mehrdad ^b   Sheng, Morgan ^a   Scearce Levie, Kimberly ^a   Zhou, Qiang ^a  

^a GENENTECH INC   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

Down syndrome; GluN2B; interneuron; LTP; memory; oscillation

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN SLICE; COGNITIVE DEFECT; CONTROLLED STUDY; DOWN SYNDROME; DRUG ANTAGONISM; GABAERGIC SYSTEM; INTERNEURON; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; OSCILLATION; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL;

ACTION POTENTIALS; ANIMALS; BRAIN WAVES; DOWN SYNDROME; EXCITATORY POSTSYNAPTIC POTENTIALS; GABAERGIC NEURONS; HIPPOCAMPUS; INTERNEURONS; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY; MICE; MICE, NEUROLOGIC MUTANTS; NEURONAL PLASTICITY; PIPERIDINES; PYRAMIDAL CELLS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84878593554     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.19     Document Type: Article

References (38)

1. Bracci E, Vreugdenhil M, Hack SP, Jefferys JG (1999). On the synchronizing mechanisms of tetanically induced hippocampal oscillations. J Neurosci 19: 8104-8113.
2. Braudeau J, Delatour B, Duchon A, Lopes-Pereira P, Dauphinot L, de Chaumont F et al (2011). Specific targeting of the GABA-A receptor {alpha}5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J Psychopharmacol 25: 1030-1042.
3. Calon F, Rajput AH, Hornykiewicz O, Bedard PJ, Di Paolo T (2003). Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14: 404-416.
4. Chakrabarti L, Best TK, Cramer NP, Carney RS, Isaac JT, Galdzicki Z et al (2010). Olig1 and Olig2 triplication causes developmental brain defects in Down syndrome. Nat Neurosci 13: 927-934.
5. Chamberland S, Topolnik L (2012). Inhibitory control of hippocampal inhibitory neurons. Frontiers Neurosci 6: 165.
6. Chazot PL (2004). The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem 11: 389-396.
7. Costa AC, Grybko MJ (2005). Deficits in hippocampal CA1 LTP induced by TBS but not HFS in the Ts65Dn mouse: a model of Down syndrome. Neurosci Lett 382: 317-322.
8. Costa AC, Stasko MR, Schmidt C, Davisson MT (2010). Behavioral validation of the Ts65Dn mouse model for Down syndrome of a genetic background free of the retinal degeneration mutation Pde6b(rd1). Behav Brain Res 206: 52-62.
9. Fernandez F, Morishita W, Zuniga E, Nguyen J, Blank M, Malenka RC et al (2007). Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci 10: 411-413.
10. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E et al (1997). Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exper Ther 283: 1285-1292.
11. Harris AZ, Pettit DL (2007). Extrasynaptic and synaptic NMDA receptors form stable and uniform pools in rat hippocampal slices. J Physiol 584(Pt 2): 509-519.
12. Kaufman AM, Milnerwood AJ, Sepers MD, Coquinco A, She K, Wang L et al (2012). Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J Neurosci 32: 3992-4003.
13. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ et al (2009). Predicting new molecular targets for known drugs. Nature 462: 175-181.
14. Kleschevnikov AM, Belichenko PV, Gall J, George L, Nosheny R, Maloney MT et al (2012). Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. Neurobiol Dis 45: 683-691.
15. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC (2004). Hippocampal long-term potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 24: 8153-8160.
16. Kocsis B (2012a). Differential role of NR2A and NR2B subunits in N-methyl-D-aspartate receptor antagonist-induced aberrant cortical gamma oscillations. Biol Psychiatry 71: 987-995.
17. Kocsis B (2012b). State-dependent increase of cortical gamma activity during REM sleep after selective blockade of NR2B subunit containing NMDA receptors. Sleep 35: 1011-1016.
18. Lei S, McBain CJ (2002). Distinct NMDA receptors provide differential modes of transmission at mossy fiber-interneuron synapses. Neuron 33: 921-933.
19. Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW et al (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27: 2846-2857.
20. Maccaferri G, Dingledine R (2002). Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J Neurosci 22: 5462-5472.
21. Mathur P, Graybeal C, Feyder M, Davis MI, Holmes A (2009). Fear memory impairing effects of systemic treatment with the NMDA NR2B subunit antagonist, Ro 25-6981, in mice: attenuation with ageing. Pharmacol Biochem Behav 91: 453-460.
22. McNally JM, McCarley RW, McKenna JT, Yanagawa Y, Brown RE (2011). Complex receptor mediation of acute ketamine applica-tion on in vitro gamma oscillations in mouse prefrontal cortex: modeling gamma band oscillation abnormalities in schizophrenia. Neuroscience 199: 51-63.
23. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD et al (2010). Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65: 178-190.
24. Mony L, Kew JN, Gunthorpe MJ, Paoletti P (2009). Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol 157: 1301-1317.
25. Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE et al (2009). Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med 15: 1407-1413.
26. Papouin T, Ladepeche L, Ruel J, Sacchi S, Labasque M, Hanini M et al (2012). Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 150: 633-646.
27. Perez-Cremades D, Hernandez S, Blasco-Ibanez JM, Crespo C, Nacher J, Varea E (2010). Alteration of inhibitory circuits in the somatosensory cortex of Ts65Dn mice, a model for Down's syndrome. J Neural Transm 117: 445-455.
28. Porter JT, Cauli B, Staiger JF, Lambolez B, Rossier J, Audinat E (1998). Properties of bipolar VIPergic interneurons and their excitation by pyramidal neurons in the rat neocortex. Eur J Neurosci 10: 3617-3628.
29. Rueda N, Florez J, Martinez-Cue C (2008). Chronic pentylenetetrazole but not donepezil treatment rescues spatial cognition in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 433: 22-27.
30. Sohal VS, Zhang F, Yizhar O, Deisseroth K (2009). Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 459: 698-702.
31. Tamamaki N, Yanagawa Y, Tomioka R, Miyazaki J, Obata K, Kaneko T (2003). Green fluorescent protein expression and colocalization with calretinin, parvalbumin, and somatostatin in the GAD67-GFP knock-in mouse. J Comp Neurol 467: 60-79.
32. Tovar KR, Westbrook GL (1999). The incorporation of NMDA receptors with a distinct subunit composition at nascent hippocampal synapses in vitro. J Neurosci 19: 4180-4188.
33. Vida I, Halasy K, Szinyei C, Somogyi P, Buhl EH (1998). Unitary IPSPs evoked by interneurons at the stratum radiatum-stratum lacunosum-moleculare border in the CA1 area of the rat hippocampus in vitro. J Physiol 506(Pt 3): 755-773.
34. von Engelhardt J, Doganci B, Jensen V, Hvalby O, Gongrich C, Taylor A et al (2008). Contribution of hippocampal and extrahippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron 60: 846-860.
35. Vreugdenhil M, Bracci E, Jefferys JG (2005). Layer-specific pyramidal cell oscillations evoked by tetanic stimulation in the rat hippocampal area CA1 in vitro and in vivo. J Physiol 562(Pt 1): 149-164.
36. Wang HX, Gao WJ (2009). Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex. Neuropsychopharmacology 34: 2028-2040.
37. Watanabe M, Inoue Y, Sakimura K, Mishina M (1993). Distinct distributions of five N-methyl-D-aspartate receptor channel subunit mRNAs in the forebrain. J Comp Neurol 338: 377-390.
38. Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD (2004). NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemiparkinsonian rats. Neuropharmacology 47: 184-194.